Bayer snaps up biotech firm Vividion Therapeutics for $2 billion

Bayer snaps up biotech firm Vividion Therapeutics for $2 billion

By Christy Gren - Aug 05, 2021

Bayer AG is in talks to buy Vividion Therapeutics in a roughly $2 billion deal, enforcing new IPO plans for Vividion.

Read More
Bristol Meyer ties up with AI pharmatech Exscientia

Bristol Meyer ties up with AI pharmatech Exscientia

By Christy Gren - May 19, 2021

Bristol-Myers Squibb, the Big Pharma company, has entered into a drug discovery collaboration worth $1.2 billion, with artificial intelligence (AI) pharmatech company, Exscientia.

Read More
Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines

Bayer plans 3 new drugs, banks on gene and cell therapy allogeneic cancer medicines

By Anna Domanska - Jan 13, 2021

German pharma giant Bayer has plans to introduce three news drugs with annual sales potential of $1.22 billion (€1 billion) but these will not offset the fall in revenue the comp

Read More